Mahesh V. Patel, Chief Executive Officer and Director of Lipocine Inc., filed a Form 4 on November 13, 2026, disclosing open-market purchases of common stock on November 12 and November 13, 2026.

Key Highlights

  • First purchase: Patel acquired 25,000 shares of common stock on November 12, 2026, at a price of $1.5796 per share.
  • Second purchase: An additional 25,000 shares were acquired on November 13, 2026, at a price of $1.5999 per share.
  • Combined acquisition: The two transactions total 50,000 shares purchased across the two-day period.
  • Post-transaction ownership: Following the November 13 purchase, Patel directly beneficially owns 211,495 shares of common stock.
  • Transaction codes: Both transactions are coded "P," indicating open-market purchases, according to the filing.
  • Roles: The filing identifies Patel as both a Director and Chief Executive Officer of Lipocine Inc.

Patel's Two-Day Purchase Activity in Lipocine Common Stock

According to the Form 4 filed with the SEC, Mahesh V. Patel, who serves as Chief Executive Officer and Director of Lipocine Inc. (NASDAQ:LPCN), reported two separate open-market purchases of the company's common stock. The filing covers transactions dated November 12 and November 13, 2026, and was signed by Patel on November 13, 2026.

The filing discloses that on November 12, 2026, Patel acquired 25,000 shares at $1.5796 per share, bringing his directly held beneficial ownership at that point to 186,495 shares. The following day, November 13, 2026, he acquired an additional 25,000 shares at $1.5999 per share, raising his directly held beneficial ownership to 211,495 shares, as reported in Table I of the filing. Both transactions carry the "P" code, which the SEC's Form 4 instructions designate as open-market or private purchases.

No derivative securities transactions were reported in Table II of this filing. The filing was made by one reporting person and is not an amendment to a prior filing, according to the form's disclosures. No Rule 10b5-1 plan checkbox was indicated as checked in this filing.

What Was Disclosed

Lipocine Inc.'s CEO and Director Mahesh V. Patel disclosed two open-market purchases of common stock totaling 50,000 shares on November 12 and November 13, 2026, at prices of $1.5796 and $1.5999 per share, respectively, resulting in direct beneficial ownership of 211,495 shares.